目的 制备紫杉醇脂质体并对其理化性质、毒性及药效学进行初步研究。方法 将大豆卵磷脂（soybean Phosphatidylcholine,SPC）、培化磷脂酰乙醇胺（mPEG2000-DSPE）及紫杉醇以100∶0.5∶5（摩尔比）混合并溶解于氯仿中,采用油水相研磨成乳,然后高压均质的方法制备脂质体。采用低速离心法测定包封率,动态光散射法测定粒度分布,KM鼠进行毒性实验,H22/KM小鼠为模型进行药效实验。结果 脂质体平均粒径为（140±10） nm;药脂摩尔比在3%～6%内包封率均大于95%;毒性实验表明,紫杉醇脂质体（Pac-lipo）和紫杉醇游离药（Pac-free）对KM雄性小鼠的最大耐受剂量（MTD）分别为64.8和29.4 mg·kg-1;药效实验表明,紫杉醇脂质体剂量依赖性的抑制鼠肝癌H22肿瘤生长。结论 紫杉醇脂质体具有较高包封率,与紫杉醇游离药相比可以显著提高治疗指数。
Abstract
Objective To prepare the paclitaxel liposomes and evaluate its physicochemical property,toxicity and pharmacodynamics. METHODS SPC,mPEG2000-DSPE and paclitaxel were dissolved in chloroform in a mole ratio of 100:0.5:5. Oil phase and water phase were mixed and skived. The emulsion was homogenized to form liposomes. The mean diameter of liposomes was determined by dynamic light scattering (DLS) techniques. Low-speed centrifugation was employed to determine encapsulation efficiency (EE). The maximum tolerated doses (MTD) was determined in normal KM mice,and antitumor effect was evaluated in H22/KM mice xenograft tumor model. RESULTS The mean diameter of paclitaxel liposomes was （140±10） nm. The EE was over 95 % when the molar ratio of paclitaxel to SPC ranged from 3% to 6%. The MTDs of Pac-lipo and Pac-free in male KM mice were 64.8 and 29.4 mg·kg-1,respectively. Pac-lipo inhibited H22 tumor weight dose-dependently．CONCLUSION Pac-lipo had a high EE,and could increase the therapeutic index significantly,compared with Pac-free.
关键词
紫杉醇 /
脂质体 /
最大耐受剂量 /
药效学
{{custom_keyword}} /
Key words
paclitaxel /
liposome /
maximum tolerated dose /
pharmacodynamics
{{custom_keyword}} /
中图分类号：
R944
{{custom_clc.code}}
({{custom_clc.text}})
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SCHIFF P B,FANT J,HORWITZ S B. Promotion of microtubule assembly in vitro by taxol . Nature,1979,277( 5698): 665-667.
[2] KANG B K,CHON S K,KIM S H,et al. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of antitumor activity in vitro and in vivo . Int J Pharm,2004,286(1/2): 147-156.
[3] RUAN G,FENG S S. Preparation and characterization of poly(lactic acid)-poly(ethylene glycol)-poly(lactic acid) (PLA-PEG-PLA) microspheres for controlled release of paclitaxel . Biomaterials,2003,24(27): 5037-5044.
[4] KANG Y M,WU Y,YANG C Q,et al. Preparation and quality study of paclitaxel liposome. China Pharm (中国药房),2008,19（28）: 2208-2210.
[5] DRUMMOND D C,NOBLE C O,GUO Z X,et al. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy . Cancer Res,2006,66(6): 3271-3277.
[6] Medigene Oncology GMBH. Method of producing a cationic liposomal preparation comprising a lipophilic compound: US,7794747 . 2010-09-14.
[7] Neopharm Inc. Method of administering liposomal encapsulated taxane: US,7314637 . 2008-01-01.
[8] WENG G Y,ZHOU W,CHENG G,et al. Paclitaxel lipid combination and preparation method: CN,00119039. 3 . 2001-04-18.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
基金
国家重点基础研究发展计划（973计划）资助项目（2010CB735603）
{{custom_fund}}
PDF(787 KB)
